Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 18/20 | 0.45 |
| ▸ | CA2 | P00918 | 18/20 | 0.45 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.45 |
| ▸ | CA4 | P22748 | 6/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935363 | 0.99 | ALDH1A1 (0.45) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL11843588 | 0.96 | CA1 (0.47) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL5797761 | 0.94 | ALDH1A1 (0.49) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL9719517 | 0.93 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL9549613 | 0.93 | ALDH1A1 (0.47) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL38651533 | 0.87 | ALDH1A1 (0.43) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL10033367 | 0.83 | SRC (0.36) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| Edetic Acid SCHEMBL10713419 | 0.81 | KDM4E (0.69) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL9719512 | 0.81 | HSD17B10 (0.44) | ALDH1A1HSD17B10KDM4EHPGDCA1 | |
| SCHEMBL5705751 | 0.80 | CA1 (0.37) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005879-A | Modified GRPR antagonist peptides for cancer imaging and treatment | 慕尼黑工业大学 | 2026-05-12 | — | — | CN | claimed |
| WO-2023245169-A1 | ANTIMICROBIAL PEPTIDE COMBINATIONS | Vestaron Corporation (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023163553-A1 | MITOCHONDRIA-TARGETING CANCER THERAPEUTIC COMPOSITION | 서울대학교산학협력단 | 2023-08-31 | — | — | WO | claimed |
| EP-0858102-B1 | Surface treatment composition and method for treating surface of substrate by using the same | MITSUBISHI CHEM CORP (JP) | 2007-07-25 | — | — | EP | claimed |
| EP-0093536-B1 | STABILISED PHOTOGRAPHIC COLOR DEVELOPER COMPOSITIONS AND PROCESSES | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-10-08 | — | — | EP | claimed |
| US-4482626-A | Photographic color developer compositions | EASTMAN KODAK COMPANY (US) | 1984-11-13 | — | — | US | claimed |
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | disclosed |
| EP-4719499-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES HARBORING MUTATIONS | Actinium Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12551584-B1 | Lewis Y radioimmunotherapy for the treatment of cancer | ACTINIUM PHARMACEUTICALS, INC. | 2026-02-17 | — | — | US | disclosed |
| US-20260000795-A1 | HER3 NANOBODIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250346589-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | UNIV ERASMUS MED CT ROTTERDAM (NL) | 2025-11-13 | — | — | US | disclosed |
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | UNIV MUENCHEN TECH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-2289869-A1 | A process for the preparation of Fe(III) chelates of N,N'-di(2-hydroxybenzyl)-ethylenediamine-N,N'-diacetic acid and its derivatives | Przedsiebiorstwo Produkcyjno-Consultingowe ADOB sp. z o.o. sp. k. (PL) | 2011-03-02 | — | — | EP | disclosed |
| WO-2011006763-A1 | A PROCESS FOR THE PREPARATION OF FE(III) CHELATES OF N,N'-DI(2-HYDROXYBENZYL)-ETHYLENEDIAMINE-N,N'-DIACETIC ACID AND ITS DERIVATIVES | PRZEDSIEBIORSTWO PRODUKCYJNO-CONSULTINGOWE ADOB SP. Z O.O. SP.K. (PL) | 2011-01-20 | — | — | WO | disclosed |
| EP-0858102-B1 | Surface treatment composition and method for treating surface of substrate by using the same | MITSUBISHI CHEM CORP (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-6228179-B1 | CONTACTING A SEMI-CONDUCTOR SUBSTRATE WITH A SURFACE TREATMENT COMPOSITION CONTAINING A COMPLEXING AGENT AS A METAL DEPOSITION PREVENTIVE IN A LIQUID MEDIUM, IN WHICH THE COMPLEXING AGENT IS AN ETHYLENEDIAMINEPHENOL DERIVATIVE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2001-05-08 | — | — | US | disclosed |
| US-6143706-A | FOR CLEANING SUBSTRATES SUCH AS SEMICONDUCTORS; PREVENTS SUBSTRATE SURFACE FROM BEING CONTAMINATED WITH METAL IMPURITIES FROM THE SURFACE TREATMENT COMPOSITION AND STABLY PROVIDES CLEAN SUBSTRATE SURFACE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-11-07 | — | — | US | disclosed |
| EP-0858102-A2 | Surface treatment composition and method for treating surface of substrate by using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-08-12 | — | — | EP | disclosed |
| EP-0093536-B1 | STABILISED PHOTOGRAPHIC COLOR DEVELOPER COMPOSITIONS AND PROCESSES | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346589-A1 | RADIOISOTOPE LABELED SSTR2-AGONISTS WITH LINKERS | SSTR2, SSTR5, SSTR1 | ALDH1A1 4607/4885HSD17B10 3620/4885KDM4E 3216/4885 |
| US-20250339567-A1 | COMPOUNDS WITH IMPROVED PHARMACOKINETICS FOR IMAGING AND THERAPY OF CANCER | RXFP2, XPNPEP2, ANTXR2 | ALDH1A1 4450/4885HSD17B10 4421/4885KDM4E 4547/4885 |
| US-12551584-B1 | Lewis Y radioimmunotherapy for the treatment of cancer | CD47, CD274, LY96 | ALDH1A1 3084/4885HSD17B10 4521/4885KDM4E 710/4885 |
| US-20260000795-A1 | HER3 NANOBODIES | ERBB2, ERBB3, BCR | ALDH1A1 4325/4885HSD17B10 2696/4885KDM4E 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.